Conversely, HER2 mutations, not HER2 overexpression, have been associated with the response of lung cancer to anti-HER2 ADCs [368], and stronger established drivers might represent better therapeutic targets [369]. The gene discussed is ERBB2; the disease is lung carcinoma.